← back to search

William P. Tew

Hesco (United States) · US
Area of research
Reproductive Medicine · Obstetrics and Gynecology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Endometrial and Cervical Cancer Treatments, Frailty in Older Adults, and PARP inhibition in cancer therapy.
h-index
56
citations
15,204
works
391
NIH funding
primary concept
Medicine
email

Recent publications

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Journal of Clinical Oncology 2025cited by 61position: lastdoi
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
Nature Medicine 2024cited by 25position: middledoi
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer
Clinical Cancer Research 2024cited by 15position: middledoi
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
Journal of Clinical Oncology 2023cited by 409position: middledoi
Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data
American Society of Clinical Oncology Educational Book 2023cited by 43position: lastdoi
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial
Journal of Clinical Oncology 2022cited by 37position: middledoi
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021
Journal of the National Comprehensive Cancer Network 2021cited by 192position: middledoi
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study
Journal of Clinical Oncology 2021cited by 123position: middledoi
Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates
Cornea 2021cited by 25position: middledoi
Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States
Journal of Geriatric Oncology 2020cited by 43position: middledoi
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Cancer 2019cited by 71position: middledoi
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Clinical Cancer Research 2018cited by 164position: middledoi
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
JAMA Oncology 2018cited by 90position: middledoi
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
Gynecologic Oncology 2018cited by 47position: middledoi
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
Gynecologic Oncology 2017cited by 81position: middledoi
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology 2016cited by 409position: middledoi
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
Gynecologic Oncology 2016cited by 365position: middledoi
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016
Journal of the National Comprehensive Cancer Network 2016cited by 122position: middledoi
The relationship between age, anxiety, and depression in older adults with cancer
Psycho-Oncology 2014cited by 138position: middledoi
Expanding the Indications for Radical Trachelectomy
International Journal of Gynecological Cancer 2013cited by 91position: middledoi
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Clinical Cancer Research 2012cited by 273position: middledoi
Senior Adult Oncology
Journal of the National Comprehensive Cancer Network 2012cited by 118position: middledoi
The translational imperative: Making cell therapy simple and effective
Acta Biomaterialia 2012cited by 45position: lastdoi
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
European Journal of Cancer 2012cited by 45position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jason Konner · KU Leuven4 papers (2012–2024)Heidi D. Klepin · ThedaCare4 papers (2014–2023)Carol Aghajanian · AstraZeneca (Italy)4 papers (2012–2024)Tanya M. Wildes · Hematology Oncology Associates3 papers (2012–2022)Vani Katheria · City of Hope3 papers (2014–2023)Deborah K. Armstrong · Florida State University3 papers (2016–2025)Paul Sabbatini · Memorial Sloan Kettering Cancer Center3 papers (2012–2019)Larissa A. Meyer · The University of Texas MD Anderson Cancer Center3 papers (2016–2025)Alexia Iasonos · Repsol (Spain)3 papers (2018–2024)Dee Sparacio · Los Angeles Public Library3 papers (2016–2025)Ritu Salani · University of Colorado Cancer Center3 papers (2016–2017)William Dale · City of Hope3 papers (2020–2023)Mitchell I. Edelson · Thomas Jefferson University Hospital3 papers (2016–2025)Rachel N. Grisham · Maryland Department of Health3 papers (2018–2024)Martee L. Hensley · Memorial Sloan Kettering Cancer Center3 papers (2012–2019)Supriya G. Mohile · University of Rochester Medical Center3 papers (2014–2023)Arti Hurria · City Of Hope National Medical Center3 papers (2012–2017)Roisin E. O’Cearbhaill · Maine Farmland Trust3 papers (2018–2025)Alexander Olawaiye · Gynecologic Oncology Group3 papers (2016–2025)William A. Cliby · Mayo Clinic3 papers (2016–2025)